Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)

Market Cap	9.44B
Revenue (ttm)	50.29M +6,162.4%
Net Income	-1.11B
EPS	-14.02
Shares Out	134.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	287,889
Open	68.30
Previous Close	68.30
Day's Range	67.30 - 68.60
52-Week Range	37.55 - 92.20
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About TPEX:7871

Elixiron Immunotherapeutics (Cayman) Limited engages in the development of precision-targeted immunotherapy drugs in Shanghai, Taipei, the United States and Switzerland. It develops EI-1071, a small molecule inhibitor of CSF-1R used for the treatment of Alzheimer's disease and amyotrophic lateral sclerosis; EI-001 for the treatment of vitiligo and Hemophagocytic Lymphohistiocytosis (HLH); and EI-012, a monoclonal antibody and EI-220 mRNA for the treatment of cancer. Elixiron Immunotherapeutics (Cayman) Limited was incorporated in 2017 and is he...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7871

Financial Performance

In 2025, TPEX:7871's revenue was 50.29 million, an increase of 6162.39% compared to the previous year's 803,000. Losses were -1.11 billion, 151.3% more than in 2024.